Fibrosis News and Research

RSS

Fibrosis is the growth of fibrous tissue.

New data from Boehringer Ingelheim's tiotropium Respimat Phase III UniTinA-asthma programme

Tiotropium delivered once daily via Respimat significantly improved lung function and reduced asthma exacerbations in patients who remain symptomatic despite treatment with at least ICS/LABA, irrespective of their allergic status.

24 Feb 2013

Janssen submits simeprevir regulatory application in Japan to treat HCV

Medivir AB today announced that its partner Janssen now has submitted a regulatory application to the Japanese Ministry of Health & Welfare authorities seeking approval for simeprevir, administered with pegylated interferon (Peg-IFN) and ribavirin (RBV) for the treatment of genotype 1 chronic hepatitis C patients who are treatment naïve, prior non responders or relapsed following treatment with Peg-IFN with or without RBV.

22 Feb 2013

Quest Diagnostics offers access to a new non-invasive prenatal test developed by Natera

Quest Diagnostics (NYSE:DGX), the world’s leading diagnostic information services company, and Natera, a leading innovator in prenatal genetic testing, today announced that Quest Diagnostics will offer physicians access to Panorama™, a new non-invasive prenatal test developed by Natera.

From Quest Diagnostics 21 Feb 2013

Researchers explore cellular signals produced by the body in response to traumatic injury

When it comes to healing the terrible wounds of war, success may hinge on the first blood clot - the one that begins forming on the battlefield right after an injury. Researchers exploring the complex stream of cellular signals produced by the body in response to a traumatic injury believe the initial response - formation of a blood clot - may control subsequent healing.

18 Feb 2013

New approach could make gene therapy dramatically more effective for HIV patients

A research team from Case Western Reserve University School of Medicine has discovered an approach that could make gene therapy dramatically more effective for patients.

16 Feb 2013

FDA committee recommends approval of Guerbet’s Dotarem NDA for adults and children

Guerbet, the contrast agent specialist for medical imaging, today announced that the Medical Imaging Drugs Advisory Committee to US Food and Drug Administration (FDA) has voted unanimously by votes of 17 to 0 to recommend that FDA approve the New Drug Application (NDA) for Dotarem (gadoterate meglumine) for adults, and for pediatric use for children two years of age and older.

15 Feb 2013

LLS, The Myeloproliferative Neoplasm Research Foundation issue MF Challenge Grant

In 2012, The Myeloproliferative Neoplasm (MPN) Research Foundation and The Leukemia & Lymphoma Society (LLS) jointly issued the MF Challenge Grant , seeking innovative approaches to reversing fibrosis in patients with myelofibrosis (MF).

15 Feb 2013

LASAG trial for severe influenza initiated

...

12 Feb 2013

MRI promising for noninvasive hepatic steatosis assessment

Magnetic resonance imaging allows accurate measurement of the extent and severity of hepatic steatosis in patients with nonalcoholic fatty liver disease, demonstrate the results of two studies published in Radiology.

11 Feb 2013

DHA more effective than EPA in preventing liver inflammation and fibrosis

Research at Oregon State University has found that one particular omega-3 fatty acid has a powerful effect in preventing liver inflammation and fibrosis - common problems that are steadily rising along with the number of Americans who are overweight.

6 Feb 2013

Interferon retreatment warning in HCV

Hepatitis C virus patients who do not respond to interferon should not receive further treatment with the drug, say the authors of a new Cochrane review.

4 Feb 2013

New method for detecting cancer by measuring elasticity of tumours

As the first countries in the world, Norway and France will be testing a completely new method for detecting cancer. This is done by measuring the elasticity of tumours. The method is called elastography. You may as well learn this new word right away; in a few years, elastography may be as common as X-rays.

4 Feb 2013

Galectin submits GR-MD-02 IND application with FDA for treatment of liver fibrosis

Galectin Therapeutics, the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced today that it submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) on January 30, 2013.

1 Feb 2013

IL-13 protein could be the key to development of fibrosis in Crohn's disease

New research has shown that a protein, known as IL-13, could be the key to the development of fibrosis in Crohn's disease. This breakthrough could help to advance new medicines to treat people suffering with the disease.

30 Jan 2013

Daily antibacterial baths can safely reduce risk of bloodstream infections in critically ill children

Daily baths with an ordinary antibacterial cleanser can safely reduce the risk of dangerous bloodstream infections in critically ill children, according to a trial conducted in five pediatric hospitals and led by investigators at the Johns Hopkins Children's Center.

28 Jan 2013

LOX enzyme can create scarred microenvironment that enhances cancer spreading

What to fear most if faced by a cancer diagnosis is the spread of the cancer to other parts of the body. This process called metastasis accounts for over 90% of cancer patient deaths and therefore is a strong focus for cancer researchers.

28 Jan 2013

Researchers to develop new diagnostic tools and treatments for people with rare diseases

A multi-million Euro initiative is bringing together researchers from across the world to develop new diagnostic tools and new treatments for people with rare diseases and to connect research data in this area on a global scale.

25 Jan 2013

Normalizing p62 protein levels in immune system cells could reduce infection in CF patients

New research suggests that lowering excessive levels of a protein in immune system cells could be a strategy to clear an infection that is deadly to patients with cystic fibrosis (CF).

23 Jan 2013

Galectin Therapeutics' GR-MD-02 reverses diabetic nephropathy in preclinical study

Galectin Therapeutics, the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced new preclinical data on the efficacy of anti-galectin therapy on diabetic kidney disease.